K
Koji Nishino
Researcher at Niigata University
Publications - 28
Citations - 409
Koji Nishino is an academic researcher from Niigata University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 10, co-authored 20 publications receiving 312 citations.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial
Toru Sugiyama,Aikou Okamoto,Takayuki Enomoto,Tetsutaro Hamano,Eriko Aotani,Yasuhisa Terao,Nao Suzuki,Mikio Mikami,Nobuo Yaegashi,Kiyoko Kato,Hiroyuki Yoshikawa,Yoshihito Yokoyama,Hiroshi Tanabe,Koji Nishino,Hiroyuki Nomura,Jae Weon Kim,Byoung-Gie Kim,Byoung-Gie Kim,Sandro Pignata,Jérôme Alexandre,John Green,Seiji Isonishi,Fumitoshi Terauchi,Keiichi Fujiwara,Daisuke Aoki +24 more
TL;DR: No significant survival benefit was found for CPT-P in patients with CCC, and both regimens were well tolerated, but the toxicity profiles differed significantly.
Journal ArticleDOI
Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.
Chiaki Banzai,Koji Nishino,Jinhua Quan,Kosuke Yoshihara,Masayuki Sekine,Tetsuro Yahata,Kenichi Tanaka +6 more
TL;DR: The methylation rate of the DAPK1 gene promoter was significantly higher in cervical cancer tissues than in cervical intraepithelial neoplasia and normal cervical tissues, and may be related to the progression of cervical oncogenesis.
Journal ArticleDOI
Cigarette smoking and glutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer.
TL;DR: The role of tobacco smoking and polymorphisms of carcinogen metabolism genes in cervical carcinogenesis are studied to elucidate the role of cancer-causing substances in women's health.
Journal ArticleDOI
Increased incidence of brain metastases in BRCA1-related ovarian cancers.
TL;DR: Examination of the BRCA1 mutation and expression profiles in ovarian cancer cases with brain metastases found no clear relationship to any known metastatic behavior.
Journal ArticleDOI
Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
Koji Nishino,Yoichi Aoki,Takayuki Amikura,Hiroaki Obata,Masayuki Sekine,Tetsuro Yahata,Kazuyuki Fujita,Kenichi Tanaka +7 more
TL;DR: This preliminary study shows that the combination of CPT-M appears to be safe and useful in patients with OCCA, and Prospective randomized trials should be conducted to assess this regimen appropriate for women with O CCA.